Biomemory Launches DNA Shield for Secure Synthetic DNA Data Storage
Biomemory introduces a commercial molecular IT service to protect critical offline digital assets.
1Synthetic DNA Storage Unveiled
Biomemory has officially launched DNA Shield, a commercial service designed to store critical digital assets within synthetic DNA. This platform provides an offline, airgapped repository for cold data, ensuring information remains immune to cyberattacks. By utilizing engineered encoding schemes, the company aims to protect sensitive records from both malicious actors and emerging AI threats.
2Targeting Cold Data Resilience
Cold data currently accounts for 60% of global information, representing records that require long-term preservation without alteration. Biomemory targets this specific segment, offering a solution for passwords, biometrics, and proprietary intellectual property. The system functions as a physical molecule, storing information indefinitely without the need for constant power or cloud connectivity.
3Strategic Acquisition and Growth
The launch of DNA Shield follows Biomemory’s strategic acquisition of Boston-based storage pioneer Catalog Technologies in March 2026. This move bolsters their technical capabilities in molecular IT. By integrating these assets, the company aims to provide a storage medium that is a million times denser than traditional magnetic storage, offering a 150-year lifespan.
4Commercializing Molecular IT
CEO Laurent Guengant describes DNA Shield as the transition from scientific proof to a viable commercial product. The service allows organizations to secure cryptographic keys and regulated records in a location inaccessible to standard cloud vendors. This initiative marks the company's entry into the emerging field of molecular IT, focusing on operational reliability.
5Pilot Program and Timeline
Availability for the DNA Shield service is currently restricted to a select group of pilot participants. These trials commenced on October 15, 2026, and are scheduled to run until mid-2027. Following the completion of this pilot phase, Biomemory plans to roll out the full commercial service to a wider range of enterprise clients globally.
6Operational Reliability Focus
Vincent Franceschini, Vice President of Product Management, emphasizes that this is the first time customers are relying on their molecular platform for operational needs rather than research. The team has spent years industrializing the encoding and recovery processes. Ensuring end-to-end integrity remains the primary technical challenge as they bring this molecular product to market.
7Subscription and Access Model
Organizations interested in securing their critical assets through DNA Shield can apply for early access directly via Biomemory. The commercial model is structured as a subscription service, with pricing starting at €10,000 per month. This fee structure reflects the specialized nature of synthetic DNA storage and the high-security requirements of the target market.
8Industry Leadership Implications
As a co-chair of the DNA Data Storage Alliance, Biomemory is positioning itself as a leader in the molecular IT space. By providing a solution that functions independently of traditional systems, they address the growing need for data sovereignty. This development signals a shift in how institutions might manage their most sensitive, long-term digital memory.